ReForm Biologics Announces Issuance of U.S. Patent on Additional Excipients for Therapeutic Protein Formulations

Excipient composition enhances viscosity reduction of therapeutic protein formulations

WOBURN, Mass.–(BUSINESS WIRE)–ReForm Biologics, a pharmaceutical technology company developing innovative platforms to improve biologic formulations, expanded its patent portfolio with the issuance of U.S. Patent No. 10,478,498 (the ‘498 patent). This patent, entitled “Excipient Compounds for Biopolymer Formulations,” provides ReForm exclusive rights to certain formulations containing combinations of its proprietary excipients that significantly enhance the viscosity reduction of the highly concentrated therapeutic formulations. ReForm has protected certain viscosity reducing excipients in two previous patents, U.S. Patent No. 9,605,051 and U.S. Patent No. 9,867,881.

Highly concentrated protein solutions with low viscosity can facilitate the delivery of biotherapeutics by subcutaneous injection or via specialized devices, while more viscous solutions have to be delivered intravenously. ReForm believes that subcutaneous injection, as enabled by viscosity reduction, offer a preferable alternative to intravenous infusions for delivering antibody therapeutics to patients, with increased patient convenience and compliance, and reduced healthcare costs.

“Therapeutic antibodies represent an important class of biopharmaceuticals for improved patient treatment, but the ability to deliver and store highly concentrated, viscous antibody formulations remains a major challenge for biopharmaceutical companies,” said John M. Sorvillo, PhD, Chief Executive Officer. “The ‘498 patent broadens our innovative platform, using combinations of our proprietary viscosity-reducing excipients for biotherapeutic formulations.”

ReForm has previously announced agreements with Astellas Pharma Inc., Bayer AG, and KBI Biopharma, Inc. to enhance the formulations of biologics based on ReForm’s patented technology.

About ReForm Biologics

ReForm Biologics has developed a technology platform that transforms the formulation of biotherapeutics for the ultimate benefit of patients. Our patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for our biopharmaceutical partners. With multiple industry alliances to date, we offer formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics.

We don’t make biologics — we make biologics better. www.reformbiologics.com

Contacts

Rob Kloppenburg

Shoreline Biotech Communications

(617) 930-5595